Drug Combination in Clinical Cancer Treatments
Aim: The modality of anticancer drug combinations needs to be renovated from empirical into technical-supportive systems. Methods: To challenge past therapeutic routines, the new landscape may be established. Among the different areas of anticancer drug combination study, research in the fields of medical study is the most important one-including disciplinary of therapeutics in different cancer stages, modern genetic/ molecular diagnostics, cancer bioinformatics, traditional Chinese medicine, mathematical data analysis, therapeutic toxicity monitor, personalized cancer medicine and so on. Discussion: This article addresses these types of cancer therapeutic management systems for clinical anticancer drug combination utilities. Conclusion: Future cancer drug combinational studies and clinical optimums must be implemented..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Reviews on recent clinical trials - 12(2017), 3, Seite 202-211 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Da-Yong Lu [VerfasserIn] |
|---|
| Links: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1998553876 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1998553876 | ||
| 003 | DE-627 | ||
| 005 | 20230511083003.0 | ||
| 007 | tu | ||
| 008 | 171125s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20171228 |
| 035 | |a (DE-627)OLC1998553876 | ||
| 035 | |a (DE-599)GBVOLC1998553876 | ||
| 035 | |a (PRQ)benthamscience_primary_http_www_eurekaselect_com_openurl_content_php_genre_article_issn_1574_8871_volume_12_issue_3_spage_2020 | ||
| 035 | |a (KEY)0598973620170000012000300202drugcombinationinclinicalcancertreatments | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ZDB |
| 100 | 0 | |a Da-Yong Lu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug Combination in Clinical Cancer Treatments |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Aim: The modality of anticancer drug combinations needs to be renovated from empirical into technical-supportive systems. Methods: To challenge past therapeutic routines, the new landscape may be established. Among the different areas of anticancer drug combination study, research in the fields of medical study is the most important one-including disciplinary of therapeutics in different cancer stages, modern genetic/ molecular diagnostics, cancer bioinformatics, traditional Chinese medicine, mathematical data analysis, therapeutic toxicity monitor, personalized cancer medicine and so on. Discussion: This article addresses these types of cancer therapeutic management systems for clinical anticancer drug combination utilities. Conclusion: Future cancer drug combinational studies and clinical optimums must be implemented. | ||
| 700 | 0 | |a Ting-Ren Lu |4 oth | |
| 700 | 0 | |a Nagendra Sastry Yarla |4 oth | |
| 700 | 0 | |a Hong-Ying Wu |4 oth | |
| 700 | 0 | |a Bin Xu |4 oth | |
| 700 | 0 | |a Jian Ding |4 oth | |
| 700 | 0 | |a Hong Zhu |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Reviews on recent clinical trials |d Saif Zone, Sharjah [u.a.] : Bentham, 2006 |g 12(2017), 3, Seite 202-211 |w (DE-627)518259552 |w (DE-600)2251879-4 |x 1574-8871 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2017 |g number:3 |g pages:202-211 |
| 856 | 4 | 2 | |u http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1574-8871&volume=12&issue=3&spage=202 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2017 |e 3 |h 202-211 | ||